Adrafinil

Adrafinil Snonymy: Adrafinil CAS.:63547-13-7 CB No.:CB7245226 M.F.:C15H15NO3S M.W.:289.35 ATC code: N06BX17 PubChem: CID: 3033226 DrugBank: DB08925 ChemSpider: 2297976 Yes UNII: BI81Z4542G Yes KEGG： D07348 Yes ChEMBL： CHEMBL93077 Yes Synonyms： CRL-40028 Legal status AU: Prescription Only (S4) Routes of administration: Oral Bioavailability: 80% Biological half-life: 1 hour Excretion: Renal Adrafinil (Olmifon) is a wakefulness-promoting agent (or eugeroic) used to relieve excessive sleepiness and inattention. It is also used off-label by individuals wishing to avoid fatigue, such as night workers or others who need to stay awake and alert for long periods of time. Adrafinil is a prodrug; it is primarily metabolized in vivo to modafinil, resulting in nearly identical pharmacological effects. Unlike modafinil, however, it takes time for the metabolite to accumulate to active levels in the bloodstream. Effects usually are apparent within 45-60 minutes when taken orally on an empty stomach. Adrafinil does not currently have FDA approval and is thus unregulated in the United States. It was marketed in France and elsewhere in Europe under the trade name Olmifon until September 2011 when France's FDA-equivalent reassessed the drug and withdrew marketing permission, citing known adverse reactions and an unsatisfactory risk to benefit ratio.